We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Acute Lymphoblastic Leukemia Risk Linked to Genetically Mediated Increase in Lymphocytes

By LabMedica International staff writers
Posted on 15 Sep 2021
Print article
Image: Acute lymphoblastic leukemia: bone marrow aspirate smear reveals increased blasts which are small to medium in size with high nuclear-to-cytoplasmic ratios, round to irregular nuclei, smooth chromatin, and scant basophilic agranular cytoplasm. Some background maturing myeloid cells are also present in this case (Photo courtesy of Karen M. Chisholm, MD, PhD)
Image: Acute lymphoblastic leukemia: bone marrow aspirate smear reveals increased blasts which are small to medium in size with high nuclear-to-cytoplasmic ratios, round to irregular nuclei, smooth chromatin, and scant basophilic agranular cytoplasm. Some background maturing myeloid cells are also present in this case (Photo courtesy of Karen M. Chisholm, MD, PhD)
Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. As an acute leukemia, ALL progresses rapidly and is typically fatal within weeks or months if left untreated.

ALL is the most common cancer among children under 15 years old and is thought to develop under a two-hit model, under which a preleukemic clone develops in utero and a second somatic mutation then spurs the development of leukemia. While some genetic risk loci linked to ALL include variants in genes that have also been associated with hematopoiesis, lymphoid development, and blood-cell traits.

Genetic Epidemiologists at the University of Southern California (Los Angeles, CA, USA) and their colleagues investigated the etiological relevance of dysregulated blood-cell homeostasis in a genome-wide association study (GWAS) of childhood ALL (2,666 affected individuals, 60,272 control individuals) and a multi-trait GWAS of nine blood-cell indices in the UK Biobank. They examined blood cell traits such as lymphocyte, platelet, and neutrophil counts, as well as neutrophil-to-lymphocyte ratios and platelet-to-lymphocyte ratios.

The investigators reported that about 3,000 genetic variants were associated with one or more of these hematological traits and explained between 4% and nearly 24% of the variation in those traits. Additionally, 115 loci were linked to blood-cell ratios. They uncovered positive correlations between increased lymphocyte counts, lymphocyte-to-monocyte ratio, and neutrophil levels with ALL risk, and an inverse correlation between a higher platelet-to-lymphocyte ratio and ALL risk.

A clustering analysis identified two putative novel ALL risk variants from among those associated with blood cell traits, one on chromosome 2q22.1 and one within the FLT3 gene on 13q12.2. The scientists noted that variants within FLT3 have recently been linked to an increased risk of autoimmune thyroid disease and acute myeloid leukemia (AML). The allele linked to both ALL and AML risk lead to a truncated FLT3 protein, but an increase in FLT3 ligand levels. While this variant has a greater effect on the development of myeloid cells, they said it could also affect ALL risk through its activation of the RAS/MAPK pathway.

The authors concluded that their study showed that a genetically induced shift toward higher lymphocyte counts, overall and in relation to monocytes, neutrophils, and platelets, confers an increased susceptibility to childhood ALL. The study was published on August 31, 2021 in the American Journal of Human Genetics.

Related Links:
University of Southern California

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.